Phase 1 · NCT05959096
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
Effect of Injection Site on the Relative Bioavailability of a Single Dose of LY3437943 in Healthy Participants With a High Body Mass Index
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Healthy Participants With a High Body Mass Index
- ClinicalTrials.gov ID
- NCT05959096
- Indication
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 85
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: LY3437943
- Comparator
- Not reported
- Eligible ages
- 18 Years – 70 Years
- Locations
- 1 site · United States
- Study start
- 18 Jul 2023
- Primary completion
- 25 Jul 2024
- Study completion
- 25 Jul 2024
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 1 Oct 2024
Endpoints
Primary
Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943; Part A: PK: Maximum Concentration (Cmax) of LY3437943
Secondary
Part B: PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943; Part B: PK: Maximum Concentration (Cmax) of LY3437943